Navigation Links
MediSapiens Gets $ 1 Million for World's First Personalized Cancer Medicine Software
Date:6/1/2010

HELSINKI, June 1, 2010 /PRNewswire/ -- MediSapiens, world's first software company for personalized cancer medicine in oncology clinics and drug development, completed $ 1 million (EUR 0.8 million) seed round investment from Veraventure, ETFIII advised by Eqvitec Partners, VTT Ventures and Lifeline Ventures.

MediSapiens is based on scientific research at the VTT Technical Research Centre of Finland and its collaborators. MediSapiens hosts world's largest unified gene expression database of human tissues and diseases. This enables scientists to understand the role of human genes in health and disease - to be applied in helping oncologists in choosing optimal treatments and biopharmaceutical companies in developing next generation personalized medicines.

"The latest research - such as The Cancer Genome Atlas funded by the NIH - demonstrates that every patient's cancer is a complex, unique combination of genetic mutations and abnormally expressed genes. The MediSapiens software gives personalized and clinically applicable insight into each patient's cancer," says Tommi Pisto, CEO and Co-founder of MediSapiens.

"Making use of the data produced by the global scientific community provides a new and significant opportunity to understand cancer. Oncologists can benefit when these reference datasets are used to interpret molecular profiling results for individual patients," comments Professor Olli Kallioniemi, MediSapiens board member and director of the Institute for Molecular Medicine Finland (FIMM).

About MediSapiens

MediSapiens, the world's first software company for personalized cancer medicine in oncology clinics and new drug development, hosts world's largest unified gene expression database. With the data online, oncologists have access to evaluate individual patient's genetic signature for the optimized treatment strategy, and scientists understand how genes work across all human tissues. Company's bioinformatics science and peer-reviewed data is based on the research since 2005 by VTT Technical Research Centre of Finland and its collaborators. Visit http://www.medisapiens.fi for more information.

About Veraventure

Veraventure, with assets under management exceeding EUR 100m, is one of the largest early stage funds in Nordic countries. Veraventure makes direct investments in early-stage research, development and innovation intensive enterprises. It also acts as the hub for early-stage venture capital and angel investors as it manages national business angel network with over 100 registered angel investors. Visit http://www.veraventure.fi/company for more information.

About Eqvitec

Eqvitec Partners is one of the largest technology oriented private equity firms in Northern Europe. The company was founded in 1997 and employs 10 investment professionals in Helsinki and Stockholm. Eqvitec Partners currently advises three funds with a total capital base of over EUR 300 million. The funds invest in technology companies in the expansion stage. At the moment the funds have investments in 30 companies and have carried out over 40 exits. Visit http://www.eqvitec.com for more information.

About VTT Ventures

VTT Ventures Ltd is a development company that generates and develops spin-offs based on VTT's technology. We work closely with more than 2,500 VTT researchers and scientists to find the most valuable new technologies to commercialize. Through us, entrepreneurs have access to innovative ideas and know-how of more than 300 patent families. This is the bases for the dealflow that enables us to create growth companies with global potential. Visit http://www.vttventures.fi for more information.

About Lifeline Ventures

Lifeline Ventures, a venture accelerator and early-stage investment fund, co-creates growth companies in health and technology. Being entrepreneurs, we are active team members for an early-stage venture for 12-24 months. Visit http://www.lifelineventures.com for more information.

    Media contact:

    Timo Ahopelto
    VP Strategy
    MediSapiens
    Email: timo.ahopelto@medisapiens.fi
    Telephone: +358-400-569-628


'/>"/>
SOURCE MediSapiens Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alexza Secures $25 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
2. Phreesia to Accelerate Growth with $16 Million Investment Led by Ascension Health Ventures
3. Karmanos Cancer Institutes Delphinus Receives $8 Million in Venture Capital for Product Development of Breast Cancer Imaging Tool
4. Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits
5. Ortho-McNeil Pharmaceutical, LLC Pleads Guilty to Illegal Promotion of Topamax and is Sentenced to Criminal Fine of $6.14 Million
6. AstraZeneca Donates $1 Million for Christiana Care Health Systems Wilmington Hospital Project
7. Winner Medical Group Inc. Announces Exercise of Over-Allotment Option Bringing Aggregate Net Proceeds of the Public Offering to $8.8 Million
8. Breathe Technologies Secures $23 Million in Series C Financing
9. ThromboGenics and BioInvent to Receive EUR10 Million Milestone as Partner Roche Begins New Clinical Study with TB-403
10. Curexo Technology Corporation Raises $13.2 Million
11. Alexza Executes $15 million Working Capital Loan with Hercules Technology Growth Capital, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... -- Corin Group announced today the launch of the Humelock ... with both a massive rotator cuff tear and a ... cuff tear arthropathy, causes pain and reduced mobility in ... Reversed Shoulder System, which was developed by FX Solutions, ... Lyon, France , received FDA clearance for ...
(Date:2/22/2017)... , Feb 22, 2017 Research and ... Drug Development Pipeline Review, 2016" report to their offering. ... ... disorders worldwide, and approximately one-third of the US population suffers ... decades, the majority of the dermatology market has remained saturated ...
(Date:2/22/2017)... Research and Markets has announced the addition of ... Small Molecule Drugs), By Route of Administration (Systemic, Topical), By ... report to their offering. ... The global psoriasis drugs market is anticipated ... report provides a detailed analysis of the current and future ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... ... their newest advanced absorption cannabidiol (CBD) serum, “NANOCALM 300” Microemulsified Hemp Extract. ... provides instant absorption from the mouth into the bloodstream. Far outpacing ...
(Date:2/22/2017)... ... February 22, 2017 , ... ANGLESTRONG , the new ... now available on the App Store and Google Play . Florida-based ... the addiction and recovery industry, partnered with Angle to build ANGLESTRONG. The new recovery ...
(Date:2/22/2017)... ... February 22, 2017 , ... Bellus Medical, a ... innovation in the delivery of Platelet Rich Plasma (PRP). PRP systems are used ... to accelerate tissue synthesis and provide a faster and more efficient healing process. ...
(Date:2/22/2017)... ... February 22, 2017 , ... Forty-five ... of those report that family members or friends have also commented about their ... hearing loss wear hearing aids. One reason, suggested by 89 percent of American ...
(Date:2/22/2017)... North Carolina (PRWEB) , ... February 22, 2017 , ... ... of cats and 54% of dogs, according to the Association for Pet Obesity Prevention ... disagreed on key pet food issues such as the benefits of corn and grains, ...
Breaking Medicine News(10 mins):